Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies

Abstract Background Triple-negative breast cancer (TNBC) treatment is currently restricted to chemotherapy. Hence, tumor-specific molecular targets and/or alternative therapeutic strategies for TNBC are urgently needed. Immunotherapy is emerging as an exciting treatment option for TNBC patients. The...

Full description

Bibliographic Details
Main Authors: Yahya Ashraf, Hanane Mansouri, Valérie Laurent-Matha, Lindsay B. Alcaraz, Pascal Roger, Séverine Guiu, Danielle Derocq, Gautier Robin, Henri-Alexandre Michaud, Helène Delpech, Marta Jarlier, Martine Pugnière, Bruno Robert, Anthony Puel, Lucie Martin, Flavie Landomiel, Thomas Bourquard, Oussama Achour, Ingrid Fruitier-Arnaudin, Alexandre Pichard, Emmanuel Deshayes, Andrei Turtoi, Anne Poupon, Joëlle Simony-Lafontaine, Florence Boissière-Michot, Nelly Pirot, Florence Bernex, William Jacot, Stanislas du Manoir, Charles Theillet, Jean-Pierre Pouget, Isabelle Navarro-Teulon, Nathalie Bonnefoy, André Pèlegrin, Thierry Chardès, Pierre Martineau, Emmanuelle Liaudet-Coopman
Format: Article
Language:English
Published: BMJ Publishing Group 2019-02-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
TNBC
Human antibody-based therapy
Immunomodulation
Protease
Tumor microenvironment
Phage display
Online Access:http://link.springer.com/article/10.1186/s40425-019-0498-z

Internet

http://link.springer.com/article/10.1186/s40425-019-0498-z

Similar Items